Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers

This article was originally published in The Gray Sheet

Executive Summary

Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.

You may also be interested in...



Bard R&D To Triple In Three Years Through Savings From Plant Consolidation

Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.

Bard R&D To Triple In Three Years Through Savings From Plant Consolidation

Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.

Curon To Beef Up Sales Force For Stretta GERD System With $55 Mil. IPO

Curon Medical will use $2 mil. of its $55 mil. initial public offering for sales and marketing initiatives related to its recently launched Stretta radiofrequency system for gastroesophageal reflux disease (GERD), according to a Sept. 22 IPO prospectus filed with the Securities and Exchange Commission.

Related Content

UsernamePublicRestriction

Register

MT013208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel